## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.5% below STRENGTH zone (3.0-6.0%); PEG 3.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($547.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 1)

**1. Intuitive Surgical Announces Leadership Transition**
- Source: TradingView — Track All Markets | 20251218T220825 | Neutral | Relevance: 100%
- Intuitive Surgical, Inc. announced a leadership transition for Brian E. Miller, Ph.D., effective January 1, 2026. He will move from his current role as Chief Digital Officer to Head of Digital and AI Strategy. This information is based on an SEC filing from December 18, 2025.

**2. Assenagon Asset Management S.A. Sells 840,025 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251217T100755 | Neutral | Relevance: 100%
- Assenagon Asset Management S.A. significantly reduced its stake in Intuitive Surgical, Inc. by selling 840,025 shares, representing a 53.1% cut. Despite this institutional selling, Intuitive Surgical exceeded Q3 earnings and revenue estimates, maintaining a "Moderate Buy" consensus among analysts with an average price target of $608.79. Recent insider selling also occurred, while the company's stock shows a fifty-day moving average of $534.09.

**3. Here’s What Hit Intuitive Surgical (ISRG) in Q3**
- Source: Insider Monkey | 20251217T082700 | Somewhat-Bullish | Relevance: 100%
- Sands Capital Global Growth Fund reported challenges for Intuitive Surgical, Inc. (NASDAQ: ISRG) in Q3 2025, with shares declining due to fears about U.S. hospital budgets and a broader healthcare sector underperformance. Despite this, the company exceeded consensus expectations with strong fundamental results, including a 22% rise in Da Vinci 5 placements and stock repurchases, positioning it well for its next robot upgrade cycle. The stock closed at $554.58 on December 16, 2025, with a market cap of $198.804 billion.

**4. Can Intuitive Surgical’s Robotic Surgery Growth Justify Its Expensive Valuation in 2025?**
- Source: Simply Wall Street | 20251219T200747 | Bearish | Relevance: 100%
- Intuitive Surgical (ISRG) is experiencing significant growth in robotic-assisted surgery, but its current valuation appears expensive based on standard metrics. Despite strong market enthusiasm and leadership in its field, DCF and PE ratio analyses suggest the company is overvalued. A "Narratives" approach offers bull and bear case valuations, providing investors with different perspectives on its future worth.

**5. Voya Investment Management LLC Sells 234,370 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251219T140829 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Intuitive Surgical, Inc. ($ISRG) by selling 234,370 shares, a 26.4% trim, in the third quarter of 2025. The firm now holds 652,769 shares valued at approximately $291.7 million, representing 0.18% of the company. Despite insider selling totaling over $63 million in the last three months, analysts maintain a "Moderate Buy" consensus rating with an average price target of $611.08, following strong Q3 earnings where ISRG exceeded EPS estimates and reported 22.9% revenue growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.36 signals overvaluation risk, limited margin of safety. Forward P/E 58.7x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $205.2B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.36 |
| Forward P/E | 58.7 |
| Current P/E | 66.2 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.4% to 2.5% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.80), momentum weakening. RSI neutral at 59. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.50% (CS: 88) | Neutral |
| RSI_14 | 59.4 | Neutral |
| MACD Histogram | -1.80 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $572.47
- **Stop Loss:** $547.57 (4.3% risk)
- **Target:** $597.37 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $27,478.56
- **Portfolio %:** 27.48%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*